NEUP vs TGHL Comparison

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.

The Growhub Ltd operates as the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, the company has developed a multi-faceted approach to address industry challenges. Its business currently comprises two main divisions, which are the Traceability and Authenticity Solutions and Carbon Project Development.